FOR IMMEDIATE RELEASESeptember 2, 2015 Sherry Pollex and the Ovarian Cancer National Alliance launch “The TealAppeal” to raise ovarian cancer awarenessPollex, Ovarian Cancer National Alliance, Martin Truex Jr., and Danica … Continued
FOR IMMEDIATE RELEASE June 15, 2015 Ovarian Cancer National Alliance honored for advocacy work OCNA called “leading advocacy organization for women impacted by ovarian cancer” WASHINGTON, DC — On Saturday, … Continued
(9/11/15) By Alan D. D’Andrea, MD, Dana-Farber Cancer Institute and Harvard Medical School, and Elizabeth M. Swisher, MD, University of Washington September is Ovarian Cancer Awareness Month, when we scientists … Continued
The largest private funder of ovarian cancer research awarded $6.3 million in grants while also launching new events and partnerships (September 11, 2015) –Ovarian Cancer Research Fund (OCRF), has awarded … Continued
Ovarian Cancer Research Fund’s Luxury Shopping Event to be held at Grand Canal Shoppes at The Venetian & The Palazzo and Fashion Show, September 19-20 Las Vegas, NV – Ovarian … Continued
(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By … Continued
On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.
(8/12/15) In response to the article “An Ovarian Cancer Treatment, Recommended Since 2006, is Found to be Underused,“ published in the Health section of The New York Times on August 3, 2015, OCRF … Continued
Gynecologic Cancer Patients to Receive Support in 6 New Locations WEST CHESTER, Pa (August 10, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC today announced six new Woman to Woman … Continued
(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that … Continued
(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The … Continued
Get email updates about research news, action alerts, and ways to join the fight.
